A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS)

ConclusionOur study provided a deeper and broader understanding of abaloparatide ’s safety profiles, which would help healthcare professionals to mitigate the risk of AEs in clinical practice, a low number of unexpected AEs supporting ongoing additional pharmacovigilance.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research